Cooper Added to RMTC Task Force on Glaucine

The Racing Medication and Testing Consortium has added Dr. Carolyn Cooper to its task force charged with reviewing information on glaucine and addressing the issue of recent positives for the substance.

Cooper, director of the Canadian Pari-Mutuel Agency Equine Drug Control Program, will join the team of seven other expert veterinarians and laboratory directors from across North America. She is an experienced regulatory veterinarian and oversees the CPMA Equine Research Facility, laboratory, and the collection/shipping and analytical contracted service providers, according to an RMTC release.

"The CPMA's laboratory has several glaucine findings," RMTC executive director Dr. Dionne Benson said. "Dr. Cooper's experience with this issue will be a valuable resource in our efforts to collect and examine information on glaucine and potentially conduct research toward the development of regulatory guidelines that address it properly. We welcome her involvement in this important scientific initiative."

Glaucine is an anti-inflammatory and bronchodilatory medication.

The RMTC consists of 23 racing industry stakeholders and organizations that represent Thoroughbred, Standardbred, Quarter Horse, and Arabian racing. The organization works to develop and promote uniform rules, policies, and testing standards at the national level; coordinate research and educational programs that seek to ensure the integrity of racing and the health and welfare of racehorses and participants; and protect the interests of the racing public.